Satellos Bioscience (TSE:MSCL)
TSX:MSCL
Total Valuation
Satellos Bioscience has a market cap or net worth of C$171.86M. The enterprise value is C$41.10M.
Market CapC$171.86M
Enterprise ValueC$41.10M
Share Statistics
Satellos Bioscience has 20,831,190 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding20,831,190
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Satellos Bioscience’s return on equity (ROE) is -0.91 and return on invested capital (ROIC) is -97.07%.
Return on Equity (ROE)-0.91
Return on Assets (ROA)-0.80
Return on Invested Capital (ROIC)-97.07%
Return on Capital Employed (ROCE)-0.97
Revenue Per Employee0.00
Profits Per Employee-1.81M
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Satellos Bioscience is ―. Satellos Bioscience’s PEG ratio is 0.11.
PE Ratio―
PS Ratio0.00
PB Ratio4.17
Price to Fair Value4.17
Price to FCF-4.81
Price to Operating Cash Flow-1.38
PEG Ratio0.11
Income Statement
In the last 12 months, Satellos Bioscience had revenue of 0.00 and earned -25.31M in profits. Earnings per share was -1.73.
Revenue0.00
Gross Profit-5.09K
Operating Income-26.92M
Pretax Income-25.13M
Net Income-25.31M
EBITDA-26.92M
Earnings Per Share (EPS)-1.73
Cash Flow
In the last 12 months, operating cash flow was -23.71M and capital expenditures -5.99K, giving a free cash flow of -23.72M billion.
Operating Cash Flow-23.71M
Free Cash Flow-23.72M
Free Cash Flow per Share-1.14
Dividends & Yields
Satellos Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.04
52-Week Price Change5.78%
50-Day Moving Average13.70
200-Day Moving Average9.52
Relative Strength Index (RSI)29.96
Average Volume (3m)178.54K
Important Dates
Satellos Bioscience upcoming earnings date is Jun 2, 2026, TBA (Confirmed).
Last Earnings DateMar 27, 2026
Next Earnings DateJun 2, 2026
Ex-Dividend Date―
Financial Position
Satellos Bioscience as a current ratio of 7.77, with Debt / Equity ratio of 0.00%
Current Ratio7.77
Quick Ratio7.77
Debt to Market Cap0.00
Net Debt to EBITDA0.36
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Satellos Bioscience has paid 175.01K in taxes.
Income Tax175.01K
Effective Tax Rate>-0.01
Enterprise Valuation
Satellos Bioscience EV to EBITDA ratio is -3.93, with an EV/FCF ratio of -4.41.
EV to Sales0.00
EV to EBITDA-3.93
EV to Free Cash Flow-4.41
EV to Operating Cash Flow-4.41
Balance Sheet
Satellos Bioscience has C$27.66M in cash and marketable securities with C$0.00 in debt, giving a net cash position of C$27.66M billion.
Cash & Marketable SecuritiesC$27.66M
Total DebtC$0.00
Net CashC$27.66M
Net Cash Per ShareC$1.33
Tangible Book Value Per ShareC$1.90
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Satellos Bioscience is C$30.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetC$30.33
Price Target Upside267.69% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast27.53%